Free Trial

Quantum Biopharma (QNTM) Competitors

Quantum Biopharma logo
$17.41 +0.85 (+5.13%)
Closing price 04:00 PM Eastern
Extended Trading
$17.59 +0.18 (+1.03%)
As of 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QNTM vs. LIMN, CADL, PVLA, DBVT, SGMT, IMMP, ACB, NGNE, TVRD, and BTMD

Should you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Liminatus Pharma (LIMN), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), DBV Technologies (DBVT), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Aurora Cannabis (ACB), Neurogene (NGNE), Tvardi Therapeutics (TVRD), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

Quantum Biopharma vs. Its Competitors

Quantum Biopharma (NASDAQ:QNTM) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, Quantum Biopharma had 2 more articles in the media than Liminatus Pharma. MarketBeat recorded 2 mentions for Quantum Biopharma and 0 mentions for Liminatus Pharma. Quantum Biopharma's average media sentiment score of 0.72 beat Liminatus Pharma's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Quantum Biopharma Positive
Liminatus Pharma Neutral

1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Liminatus Pharma's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Quantum BiopharmaN/A -155.20% -94.90%
Liminatus Pharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quantum BiopharmaN/AN/A-$14.20M-$15.98-1.09
Liminatus PharmaN/AN/AN/AN/AN/A

Summary

Quantum Biopharma beats Liminatus Pharma on 4 of the 6 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QNTM vs. The Competition

MetricQuantum BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$50.63M$2.88B$5.46B$8.92B
Dividend YieldN/A2.44%5.24%4.04%
P/E Ratio-1.0920.8027.0120.12
Price / SalesN/A193.35380.1493.35
Price / CashN/A41.7026.2128.59
Price / Book3.837.487.995.57
Net Income-$14.20M-$55.04M$3.16B$248.40M
7 Day Performance-9.89%5.44%3.69%6.04%
1 Month Performance12.69%2.38%2.91%7.69%
1 Year PerformanceN/A5.53%34.30%20.97%

Quantum Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QNTM
Quantum Biopharma
N/A$17.41
+5.1%
N/AN/A$50.63MN/A-1.09N/A
LIMN
Liminatus Pharma
N/A$11.15
+17.6%
N/AN/A$246.62MN/A0.00N/AGap Up
CADL
Candel Therapeutics
2.4662 of 5 stars
$5.06
+3.3%
$22.00
+334.8%
-14.3%$245.50M$120K-3.7860
PVLA
Palvella Therapeutics
3.3354 of 5 stars
$22.54
+2.1%
$46.29
+105.3%
N/A$244.11M$42.81M-1.86N/A
DBVT
DBV Technologies
3.7165 of 5 stars
$9.16
+3.2%
$14.75
+61.0%
+162.5%$243.22M$4.15M-1.8680Analyst Upgrade
SGMT
Sagimet Biosciences
2.4052 of 5 stars
$7.62
-3.2%
$26.60
+249.1%
+193.2%$241.41M$2M-4.338
IMMP
Prima BioMed
0.9837 of 5 stars
$1.64
flat
$7.00
+326.8%
-13.4%$239.50M$5.14M0.002,021Positive News
ACB
Aurora Cannabis
0.099 of 5 stars
$4.24
+2.2%
N/A-8.1%$233.29M$246.72M38.551,130
NGNE
Neurogene
3.7905 of 5 stars
$14.95
-7.5%
$46.17
+208.8%
-42.9%$230.48M$930K-3.4490
TVRD
Tvardi Therapeutics
N/A$23.33
-5.2%
$71.50
+206.5%
N/A$230.37M$7.14M0.0080
BTMD
biote
3.0952 of 5 stars
$4.02
-4.3%
$8.00
+99.0%
-46.0%$229.78M$197.19M6.59194News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:QNTM) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners